These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17982198)

  • 1. [Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2007 Nov; 17(11):1762-8. PubMed ID: 17982198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis].
    Kotake S; Yago T; Nanke Y
    Nihon Rinsho; 2009 May; 67(5):996-1002. PubMed ID: 19432123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-RANKL antibody for the treatment of rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
    Tanaka Y
    Clin Calcium; 2010 Oct; 20(10):1545-52. PubMed ID: 20890038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
    Tanaka Y
    Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
    Nakamura T
    Clin Calcium; 2009 Mar; 19(3):381-6. PubMed ID: 19252248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologic agents for the treatment of rheumatic diseases].
    Tanaka Y
    Clin Calcium; 2014 Jun; 24(6):911-7. PubMed ID: 24870843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Anti-bone resorbing treatment for rheumatoid arthritis.].
    Tanaka Y
    Clin Calcium; 2018; 28(5):630-636. PubMed ID: 29731457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
    Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
    J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does infliximab work in rheumatoid arthritis?
    Maini RN; Feldmann M
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
    Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
    Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
    Maldonado-Gonzales E; Pietschmann P
    Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibody therapy for rheumatoid arthritis].
    Ishii T; Saeki Y
    Nihon Rinsho; 2002 Mar; 60(3):551-5. PubMed ID: 11904972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
    Tanaka Y
    Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of the joint destruction in RA by TNF-blocking agents].
    Kameda H
    Clin Calcium; 2007 Apr; 17(4):553-60. PubMed ID: 17404485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
    Nakayamada S; Tanaka Y
    Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.